dc.contributor.author |
Choi, Jennifer
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.contributor.author |
Blidner, Ada Gabriela
|
|
dc.contributor.author |
Cooksley, Tim
|
|
dc.contributor.author |
Dougan, Michael
|
|
dc.contributor.author |
Glezerman, Ilya
|
|
dc.contributor.author |
Ginex, Pamela
|
|
dc.contributor.author |
Girotra, Monica
|
|
dc.contributor.author |
Gupta, Dipti
|
|
dc.contributor.author |
Johnson, Douglas
|
|
dc.contributor.author |
Shannon, Vickie R.
|
|
dc.contributor.author |
Suarez-Almazor, Maria
|
|
dc.contributor.author |
Rapoport, Bernardo Leon
|
|
dc.contributor.author |
Lacouture, Mario E.
|
|
dc.date.accessioned |
2020-10-26T08:07:21Z |
|
dc.date.issued |
2020-12 |
|
dc.description.abstract |
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit. |
en_ZA |
dc.description.department |
Immunology |
en_ZA |
dc.description.embargo |
2021-08-20 |
|
dc.description.librarian |
hj2020 |
en_ZA |
dc.description.sponsorship |
NIH/NIAMS; the NIH/NCI Cancer Center; the Cancer Association of South Africa (CANSA) and the National Research Foundation (NRF) of South Africa. |
en_ZA |
dc.description.uri |
http://link.springer.com/journal/520 |
en_ZA |
dc.identifier.citation |
Choi, J., Anderson, R., Blidner, A. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer 28, 6119–6128 (2020). https://doi.org/10.1007/s00520-020-05706-4. |
en_ZA |
dc.identifier.issn |
0941-4355 (print) |
|
dc.identifier.issn |
1433-7339 (online) |
|
dc.identifier.other |
10.1007/s00520-020-05706-4 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/76602 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Springer |
en_ZA |
dc.rights |
© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520. |
en_ZA |
dc.subject |
Bullous dermatoses |
en_ZA |
dc.subject |
Corticosteroids |
en_ZA |
dc.subject |
Cutaneous IrAEs |
en_ZA |
dc.subject |
Inflammatory dermatitis |
en_ZA |
dc.subject |
Pruritus |
en_ZA |
dc.subject |
Skin rash |
en_ZA |
dc.subject |
Vitiligo |
en_ZA |
dc.subject |
Immune checkpoint inhibitor (ICI) |
en_ZA |
dc.subject |
Immune-related adverse events (IrAEs) |
en_ZA |
dc.title |
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors |
en_ZA |
dc.type |
Postprint Article |
en_ZA |